968 related articles for article (PubMed ID: 15001157)
21. Expression of the apoptosis inhibitor protease inhibitor 9 predicts clinical outcome in vaccinated patients with stage III and IV melanoma.
van Houdt IS; Oudejans JJ; van den Eertwegh AJ; Baars A; Vos W; Bladergroen BA; Rimoldi D; Muris JJ; Hooijberg E; Gundy CM; Meijer CJ; Kummer JA
Clin Cancer Res; 2005 Sep; 11(17):6400-7. PubMed ID: 16144945
[TBL] [Abstract][Full Text] [Related]
22. Melanoma immunology: past, present and future.
Parmiani G; Castelli C; Santinami M; Rivoltini L
Curr Opin Oncol; 2007 Mar; 19(2):121-7. PubMed ID: 17272984
[TBL] [Abstract][Full Text] [Related]
23. Melanoma cancer vaccines and anti-tumor T cell responses.
Vujanovic L; Butterfield LH
J Cell Biochem; 2007 Oct; 102(2):301-10. PubMed ID: 17647270
[TBL] [Abstract][Full Text] [Related]
24. Tumor antigen-specific FOXP3+ CD4 T cells identified in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts.
Jandus C; Bioley G; Dojcinovic D; Derré L; Baitsch L; Wieckowski S; Rufer N; Kwok WW; Tiercy JM; Luescher IF; Speiser DE; Romero P
Cancer Res; 2009 Oct; 69(20):8085-93. PubMed ID: 19808957
[TBL] [Abstract][Full Text] [Related]
25. Allogeneic and autologous melanoma vaccines: where have we been and where are we going?
Sondak VK; Sabel MS; Mulé JJ
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2337s-2341s. PubMed ID: 16609055
[TBL] [Abstract][Full Text] [Related]
26. Melanoma-associated tumor antigens and their clinical relevance to immunotherapy.
Gattoni-Celli S; Cole DJ
Semin Oncol; 1996 Dec; 23(6):754-8. PubMed ID: 8970598
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy of melanoma: the good news, the bad ones and what to do next.
Marincola FM; Ferrone S
Semin Cancer Biol; 2003 Dec; 13(6):387-9. PubMed ID: 15001156
[No Abstract] [Full Text] [Related]
28. [Immunotherapy for melanoma: how can tolerance be overcome?].
Robert C
Ann Dermatol Venereol; 2001; 128(6-7):709-13. PubMed ID: 11460031
[No Abstract] [Full Text] [Related]
29. Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy.
Kohlmeyer J; Cron M; Landsberg J; Bald T; Renn M; Mikus S; Bondong S; Wikasari D; Gaffal E; Hartmann G; Tüting T
Cancer Res; 2009 Aug; 69(15):6265-74. PubMed ID: 19622767
[TBL] [Abstract][Full Text] [Related]
30. Current developments of immunotherapy in the clinic.
Antonia S; Mulé JJ; Weber JS
Curr Opin Immunol; 2004 Apr; 16(2):130-6. PubMed ID: 15023403
[TBL] [Abstract][Full Text] [Related]
31. Melanoma antigens and targets for vaccination.
Kang N; Truman H; Sanders R; Kupsch J
Br J Hosp Med; 1997 Sep 17-30; 58(6):282-6. PubMed ID: 9488805
[TBL] [Abstract][Full Text] [Related]
32. Dendritic cell-derived exosomes in cancer immunotherapy: exploiting nature's antigen delivery pathway.
Delcayre A; Shu H; Le Pecq JB
Expert Rev Anticancer Ther; 2005 Jun; 5(3):537-47. PubMed ID: 16001959
[TBL] [Abstract][Full Text] [Related]
33. DC therapy for metastatic melanoma.
Ingram SB; O'Rourke MG
Cytotherapy; 2004; 6(2):148-53. PubMed ID: 15203991
[No Abstract] [Full Text] [Related]
34. [Active specific immunotherapy of malignant melanoma].
Lotem M; Shiloni E; Ingber A; Peretz T
Harefuah; 1997 Aug; 133(3-4):122-6. PubMed ID: 9332080
[No Abstract] [Full Text] [Related]
35. Therapeutic vaccines in solid tumours: can they be harmful?
Eggermont AM
Eur J Cancer; 2009 Aug; 45(12):2087-90. PubMed ID: 19477117
[TBL] [Abstract][Full Text] [Related]
36. [Vaccination therapy of melanoma].
Schuler-Thurner B; Schuler G
J Dtsch Dermatol Ges; 2005 Aug; 3(8):630-45. PubMed ID: 16033483
[No Abstract] [Full Text] [Related]
37. Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration.
Andersen MH; Gehl J; Reker S; Pedersen LØ; Becker JC; Geertsen P; thor Straten P
Semin Cancer Biol; 2003 Dec; 13(6):449-59. PubMed ID: 15001164
[TBL] [Abstract][Full Text] [Related]
38. Self-recognition and tumor response to immunotherapy.
Ernstoff MS
J Clin Oncol; 2005 Sep; 23(25):5875-7. PubMed ID: 16087939
[No Abstract] [Full Text] [Related]
39. [Immunotherapy in malignant melanoma].
Braathen LR; Hunger RE; Brand CU
Zentralbl Chir; 2000; 125(10):806-9. PubMed ID: 11098573
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapy for melanoma.
Komenaka I; Hoerig H; Kaufman HL
Clin Dermatol; 2004; 22(3):251-65. PubMed ID: 15262312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
